PT - JOURNAL ARTICLE AU - Susy Echeverria Londono AU - Xiang Li AU - Jaspreet Toor AU - Margaret J. de Villiers AU - Shevanthi Nayagam AU - Timothy B. Hallett AU - Kaja Abbas AU - Mark Jit AU - Petra Klepac AU - Kévin Jean AU - Tini Garske AU - Neil M. Ferguson AU - Katy A. M. Gaythorpe TI - How can the public health impact of vaccination be estimated? AID - 10.1101/2021.01.08.21249378 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.08.21249378 4099 - http://medrxiv.org/content/early/2021/01/09/2021.01.08.21249378.short 4100 - http://medrxiv.org/content/early/2021/01/09/2021.01.08.21249378.full AB - Deaths due to vaccine preventable diseases cause a notable proportion of mortality worldwide. To quantify the importance of vaccination, it is necessary to estimate the burden averted through vaccination. The Vaccine Impact Modelling Consortium (VIMC) was established to estimate the health impact of vaccination. We describe the methods implemented by the VIMC to estimate impact by calendar year, birth year and year of vaccination (YoV). The calendar and birth year methods estimate impact in a particular year and over the lifetime of a particular birth cohort, respectively. The YoV method estimates the impact of a particular year’s vaccination activities through the use of impact ratios which have no stratification and stratification by activity type and/or birth cohort. Furthermore, we detail an impact extrapolation (IE) method for use between coverage scenarios. We compare the methods, focusing on YoV for hepatitis B, measles and yellow fever. We find that the YoV methods estimate similar impact with routine vaccinations but have greater yearly variation when campaigns occur with the birth cohort stratification. The IE performs well for the YoV methods, providing a time-efficient mechanism for updates to impact estimates. These methods provide a robust set of approaches to quantify vaccination impact.Competing Interest StatementThis work was funded by GAVI, the Vaccine Alliance and Bill and Melinda Gates Foundation.Funding StatementWe thank Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation for funding VIMC (BMGF grant number: OPP1157270). SEL, XL, JT, KW, TG, NMF, KAMG also acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union; and acknowledges funding by Community Jameel.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available on request but will be available through an online data visualisation tool accessible through vaccineimpact.org, and attached to the forthcoming paper: https://www.medrxiv.org/content/10.1101/19004358v1. Code is available at: https://github.com/vimc/vimpact https://github.com/vimc/vimpact